<DOC>
	<DOCNO>NCT00985998</DOCNO>
	<brief_summary>Nimotuzumab ( hR3 ) IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . The study assess safety , efficacy combination Nimotuzumab administer concomitantly chemotherapy patient advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Nimotuzumab Combination With Cisplatin Docetaxel Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Altered expression constitutive activation epidermal growth factor receptor ( EGFR/HER1/erbB1 ) commonly occur primary NSCLC , often critical factor progressive growth resistance normal mechanism cell death . Epidermal growth factor receptor expression lung cancer correlate tumor aggressiveness . Clinical trial already suggest EGFR target therapy may improve antitumor activity chemotherapy treatment lung carcinoma . Monoclonal antibody specific EGFR combine safely effectively chemotherapy . Nimotuzumab ( hR3 ) humanize monoclonal antibody ( mAb ) bind EGFR . In preclinical study antibody show potent antitumor activity . A previous phase II study child high grade brain tumor show activity Nimotuzumab monotherapeutic agent , even prognostic unfavourable diffuse , intrinsic pontine glioma . No drug relate side effect report . Nimotuzumab ( hR3 ) combination radiotherapy treatment locally advance squamous cell carcinoma head neck result high rate antitumor response , accompany favourable safety profile . This dose-escalation study Nimotuzumab . Nimotuzumab combination chemotherapy administer patient advanced NSCLC . The patient ' blood test liver renal function test monitor weekly , physical exam reassessment tumor perform every 6 week . When total result CR PR , result 6th , 12th , 18th 22th week compare .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Subjects pathologically cytologically document stage IIIB IV NSCLC . Disease must newly diagnose . Presence least 1 unidimensionally measurable index lesion , long diameter ≥ 20 mm use conventional computer tomography ( CT ) /magnetic resonance imaging ( MRI ) scan ≥ 10 mm use spiral compute tomography scan . Age &gt; 18 &lt; 65 , ECOG performance status 01 , Life expectancy 3 month . function major organ ( haemogram , heart , liver , kidney ) basically normal , White blood count ≥3.5 x 109/L neutrophil ≥1.5 x 109/L , platelet count≥100 x 109/L , hemoglobin ≥100g/L . Total bilirubin ≤1.5 time upper limit normal ( ULN ) range ; alkaline phosphatase ( ALP ) ≤ 2.5 time ULN ≤5 time ULN ( liver metastasis ) ; Transaminases AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time ULN ≤ 5 time ULN ( liver metastasis ) . serum creatinine ≤ 1.2 time ULN , blood urea nitrogen≤ 1.2 time ULN . female male patient must use adequate method contraception . without malignancy history , except curative carcinoma situ cervix skin basal cell carcinoma . willing able comply schedule visit , treatment plan , laboratory test , study procedure . Previous radiotherapy（except radiotherapy brain metastasis） , Previous chemotherapy anticancer biotherapy , Participation clinical trial within 1 month prior inclusion trial . With unmeasureable lesion , ie , hydrothorax , ascites , lymphangitis carcinomatous , diffuse liver metastasis , bony metastasis ; measureable lesion lesion could determine . Pregnant breastfeed woman use prohibited contraceptive method . With Symptomatic brain metastasis control . uncontrolled seizure disorder , active centre neurological disease , Psychiatric disease affect cognitive ability ; physiogenic pathological dystrophinopathies , chronic diarrhea , cachexia . significant history cardiac disease , i.e. , congestive heart failure , angina require medication , uncontrolled cardiac ventricular arrythmias , heart valve disease , serious myocardial infarction , uncontrolled hypertension . With serious internal disease uncontrolled infection . With drug addition , ie , drugtaking , drugtaking long time ; AIDS . With organ transplantation , use adrenocortical hormone immunosuppressive agent long time . With history serious allergic allergy . Not fit clinical trial judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>nimotuzumab</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>